Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Alliance Pharma: Investec ups target from 28p to 28.7p, hold rating kept.
Alliance Pharma, a speciality pharmaceutical company, has said its wholly owned subsidiary, Alliance Pharmaceuticals, has acquired Opus Group Holdings for £8.0m plus the net asset value of Opus at completion (estimated at £1.5m). The Opus group sells products for stoma care, including skin creams and cleansers, in the UK and Ireland. In the year ended March 31st Opus delivered turnover of £3.8m and pre-tax profit of £2.1m. The consideration is being funded from existing cash and bank facilities.
Alliance Pharma: umps upgrades to buy, target lifted from 32p to 37p.
Alliance Pharma, a specialist pharmaceutical firm, reported a decline in half year pre-tax profit after revenue fell on the back of a 10% drop in sales. Sales for the six month period totalled £22.0m, down from £24.4m during the same period in 2011, dragging half year profit down from £7.0m to £5.3m. Basic earnings per share totalled 1.80p, compared to 2.38p the previous year. Michael Gatenby, Alliance Pharma's Chairman, said: "We are pleased with the underlying performance in the first half year. We have an attractive and robust portfolio, which, boosted by the product acquisitions we have made over the past 12 months, gives us plenty of scope for driving organic sales growth. We remain well placed to fund further acquisitions and we have substantially broadened our search for targets to include opportunities on the Continent. We are confident that Alliance will continue to make solid progress." Sales of the firm's Deltacortril / enteric coated prednisolone product now appear to have stabilised at a run rate of around £2.0m per annum, following the decline seen in early 2011 after the launch of a second generic competitor and changes in clinical preference. The Hydromol grew particularly well, recording growth of 28% in the first half, while Nu-Seals, its low dose aspirin product, experienced increased competition in Ireland. The interim dividend was increased by 10% from 0.25p to 0.275p.
Alliance Pharma, a speciality pharmaceutical company, has said trading during the six months ended June 30th has been in line with management's expectations, with turnover of around £22m. The Hydromol produce continues to perform well, with growth of 28% over the first half of 2011. The firm said it is continuing to explore a number of acquisition opportunities, some of which are at a very advanced stage. The temporary suspension of the ImmuCyst product is expected to end in late 2013.
Here you are, what happens here / over a year ago this was one of the best company on pharms on FTSE aim so what went wrong
Good Morning Inmates. I am here to say Good Bye, I hate good byes’ but enough is enough ones must know ones limits THANK YOU APH and good bye; you know I have been faithful and you have been wonderful to me because of you I could now and decide to have my retirement a little earlier, 2 steps forward. Good Bye all I wish you all good lucks and good health, be faithful like me and soon you’ll able to do like me – if this is what you wished
Scancell's Dynamite Revelation In May 2010 an astonishing revelation came to light. Scancell was to trial a vaccine that, in an earlier version, had already cured two girls of bone cancer! The elder of the two wished to remain anonymous but Amy Dickenson, by now 20 years old and pregnant with her second baby, was only too pleased to bear witness to the miracle cure which saved her life. As an eight year old, Amy was entered into a trial of the early version of Scancell's vaccine, configured at that time to treat bone cancer. In Amy's case an advanced stage of this cancer had developed in her left leg. Despite gruelling surgery and chemotherapy, the disease persisted and spread to her lungs. Amy was not expected to survive, yet she was found to be cured following the treatment. Professor Kathy Pritchard Jones, who led the trial with both girls, at the Royal Marsden Hospital in London, said: “I believe the vaccine played a vital role in their recovery. It is incredibly promising that patients with this almost incurable disease have gone on to live normal lives.” Scancell is currently engaged in new clinical trials with the latest version of the vaccine reconfigured to treat malignant melanoma, the most aggressive form of skin cancer. Designated SCIB1, this will be the first vaccine Scancell has designed for commercial use. A second vaccine to treat lung cancer is also in development. Professor Lindy Durrant, Joint CEO of Scancell commented: "In the short term, this could cure some patients with the disease, and in the long term it could be used to prevent people developing it in the first place." Professor Karol Sikora, a leading cancer expert, added: "This is a very clever vaccine and I believe it will increase the cure rate for patients in the future." The Sunday Express CANCER SCIENTISTS HAIL 'HUGE' LEAP TOWARDS JAB THAT TARGETS TUMOURS: http://www.express.co.uk/posts/view/175410/Cancer-scientists-hail-huge-leap-towards-jab-that-targets-tumours Mail Online 'HOLY GRAIL' CANCER VACCINE THAT BLASTS TUMOURS IN WEEKS HAILED AS HUGE LEAP IN FIGHTING DISEASE: http://www.dailymail.co.uk/health/article-1278836/Holy-Grail-cancer-vaccine-blasts-tumours-weeks-hailed-huge-leap-fighting-disease.html Vaccine News Daily CANCER VACCINE BREAKTHROUGH REPORTED: http://vaccinenewsdaily.com/news/213067-cancer-vaccine-breakthrough-reported/
Brewin Dolphin downgraded Alliance Pharma (APH) from "add" to "hold" with a reduced target price of 33p, from 31p. The pharmaceutical company missed the broker's pre-tax profit target for the 2011 financial year by 4%. Brewin notes a particularly poor performance from the group's Deltacortril anti-inflammatory drug, with sales 13% behind target at 4.7 million pounds. On a more positive note, the broker said that its high exposure to the UK and prescription market should make the firm more resilient against austerity measures in Europe. The shares inched down 0.125p to 28.625p.
19 December 2011 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Acquisition of Dermatology Brands Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that its wholly owned subsidiary Alliance Pharmaceuticals Limited has acquired the brands QuinodermTM and CeanelTM from Ferndale Pharmaceuticals Limited for £1.5m cash consideration. Quinoderm is a well-established medication for the treatment of acne and Ceanel is a shampoo treatment for scalp psoriasis. For the twelve months ended 30 September 2011 the acquired products had total sales of approximately £0.6 million. Alliance is funding the acquisition by drawing a loan from the £20m Revolving Credit Facility ("RCF") put in place in November 2010 to fund acquisitions. This brings the current utilisation of the RCF to £6.5m. Commenting on the acquisition, John Dawson, Alliance Pharma's Chief Executive, said: "We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year. "Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."
I like the comments and talk about china, I assume fairly defensive stock with potential. If there successful in china then must be some good money in it.
I am invested here, think that it is one of the most undervalued shares i've ever came across. Makes a good profit, decent room for growth in the market cap, Pays a dividend(Although small) and in a sector that shouldn't be too affected despite any market problems. People will still need their pills. Problem with this is it's not a flashy share, doesn't grab peoples attention and won't grow 25% over night which you MIGHT get with the small oil companies. People will come to see this for the quality it possesses. Great little share worth having a toe in.,
Does anyone talk about this share, just bought some and wondered what people's thoughts are at the minute.
The directors of Active Energy (AIM: AEG), Alliance Pharma (AIM: APH), Silence Therapeutics (AIM: SLN) and Medgenics (AIM: MEDG) will be presenting: Thursday the 23rd June 2011, Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB (Charles Suite) The presentations will start at 6:00pm and finish at approx 7:30pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below. FREE registration - http://www.proactiveinvestors.co.uk/register/event_details/114 This event is suitable for the following: Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists. The event is not suitable for people pursuing commercial opportunities. If you have any problems registering or queries please email events@proactiveinvestors.com.
Is the present sp (28.75) below expectation? Reading reports suggests a gradual return to the 30-36 levels or is this too optimistic?
Alliance Pharma cuts sales guidance By Benjamin Chiou Date: Thursday 26 May 2011 LONDON (ShareCast) - Shares in pharmaceutical company Alliance Pharma fell back on Thursday - despite a positive first four months of the year - after it cut its sales guidance of its enteric-coated prednisolone product. As previously reported, the group had warned that it is facing generic competition in relation to Deltacortil, mainly due to launch of a second generic competitor at the end of last year. While Alliance said in March that the impact had not been quite as bad as first thought, chairman Michael Gatenby said that "there has recently been increasing pressure on both price and volumes." As a result, the group has scaled back its expectations for the ongoing run rate of Deltacortil sales. However, strong trading in the first four months (with turnover 14% higher than the previous year at £17.1m) should offset the negative effect of competition. "However, we are now more cautious about the outlook for Deltacortril in 2012 as this competitive market develops," Gatenby said. --- BC
AGM Statement Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold its Annual General Meeting in London later this morning. Michael Gatenby, the Company's Chairman, will make the following comments: "I am pleased to report that trading in the first four months of 2011 has been ahead of our expectations with turnover of £17.1 million, 14% higher than the same period last year. "As previously reported, we are facing some generic competition in relation to Deltacortril / enteric coated prednisolone and have been monitoring the impact on the sales of the product since the launch of a second generic competitor towards the end of 2010. We reported in March 2011 that the impact had not been quite as significant as expected. However, there has recently been increasing pressure on both price and volumes and, as a result, we have reduced our expectations for the ongoing run rate of Deltacortril sales. Given the strong start to the year, this is not expected to significantly affect our overall performance for the current financial year. However, we are now more cautious about the outlook for Deltacortril in 2012 as this competitive market develops. "We are pleased to report that the dermatology and oncology portfolios continue to grow well. "We were delighted to announce last week the renewal of the ImmuCyst® distribution agreement and to announce last month the completion of the acquisition of AnbesolTM and Ashton & ParsonsTM. We continue to consider further acquisition opportunities."
http://www.investegate.co.uk/Article.aspx?id=201105260700153281H
Finding new drugs is an expensive, hit-or-miss affair. How much easier to pick up existing ones once in development, which is what a lot of big pharmaceutical firms do. Easier still is to buy drugs that are out of patent and so relatively cheap but still with a useful shelf life, which is what Alliance Pharma does. This year’s performance will be more subdued, partly because of the arrival of additional competition for a steroid it owns, but this has been well signalled to the market. The shares, on about ten times’ earnings, look good value if you can pick them up, reckons the Times.
These brands will sit nicely in APH's growing portfolio. Looking at the potential revenue, the borrowings to fund the purchase do not appear excessive.
Proposed acquisition Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that its wholly owned subsidiary Alliance Pharmaceuticals Limited has conditionally agreed to buy the UK and Irish rights to the brands AnbesolTM and Ashton & ParsonsTM from a subsidiary of Reckitt Benckiser Group plc ("Reckitt Benckiser") for £2.55m cash consideration. Alliance intends to fund the acquisition by drawing a loan from the £20m Revolving Credit Facility ("RCF") that was put in place in November 2010 to fund acquisitions. The RCF is not currently utilised. Anbesol is used to treat mouth ulcers, teething pains and denture irritation. Ashton & Parsons is used in infants for the symptomatic relief of pain and stomach upset caused by teething. As part of the acquisition by Reckitt Benckiser of SSL International plc, Reckitt Benckiser plc has given commitments to the European Commission to divest Anbesol and Ashton & Parsons. The sale of the brands by Reckitt Benckiser to Alliance is conditional on the approval of the European Commission. For the twelve months ended 31 December 2010 Anbesol and Ashton & Parsons sales were £1.3m and £0.8m respectively. Sales of Ashton & Parsons in the past few months have been somewhat lower than historically as a result of certain production issues which Alliance will be seeking to resolve. The gross margin rates of Anbesol and Ashton & Parsons are in line with other products in Alliance's existing portfolio. Based on the contribution from Anbesol alone, the proposed acquisition is expected to be earnings enhancing in the current financial year.
http://www.investegate.co.uk/Article.aspx?id=201103230701064399D
are coming in..gla
http://www.investegate.co.uk/Article.aspx?id=201102021238365569A